Activation of Wnt/β-catenin signalling pathway induces chemoresistance to interferon-α/5-fluorouracil combination therapy for hepatocellular carcinoma

被引:99
|
作者
Noda, T. [1 ]
Nagano, H. [1 ]
Takemasa, I. [1 ]
Yoshioka, S. [1 ]
Murakami, M. [1 ]
Wada, H. [1 ]
Kobayashi, S. [1 ]
Marubashi, S. [1 ]
Takeda, Y. [1 ]
Dono, K. [1 ]
Umeshita, K. [2 ]
Matsuura, N. [3 ]
Matsubara, K. [4 ]
Doki, Y. [1 ]
Mori, M. [1 ]
Monden, M. [1 ]
机构
[1] Osaka Univ, Dept Surg, Grad Sch Med & Hlth Sci, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Dept Hlth Sci, Grad Sch Med & Hlth Sci, Suita, Osaka 5650871, Japan
[3] Osaka Univ, Dept Mol Pathol, Grad Sch Med & Hlth Sci, Suita, Osaka 5650871, Japan
[4] DNA Chip Res Inc, Kanagawa, Japan
关键词
hepatocellular carcinoma; combination therapy; interferon-alpha; 5-fluorouracil; chemoresistance; Wnt signalling; SUBCUTANEOUS INTERFERON-ALPHA; ADVANCED GASTRIC-CANCER; GENE-EXPRESSION; INTRAARTERIAL; 5-FLUOROURACIL; STEM-CELLS; EP-CAM; HEPATIC RESECTION; TUMOR THROMBUS; STAT3; ACTIVITY; IFN-ALPHA;
D O I
10.1038/sj.bjc.6605064
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Type I IFN receptor type 2 (IFNAR2) expression correlates significantly with clinical response to interferon (IFN)-alpha/5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC). However, some IFNAR2-positive patients show no response to the therapy. This result suggests the possibility of other factors, which would be responsible for resistance to IFN-alpha/5-FU therapy. The aim of this study was to examine the mechanism of anti-proliferative effects of IFN-alpha/5-FU therapy and search for a biological marker of chemoresistance to such therapy. Gene expression profiling and molecular network analysis were used in the analysis of non-responders and responders with IFNAR2-positive HCC. The Wnt/beta-catenin signalling pathway contributed to resistance to IFN-alpha/5-FU therapy. Immunohistochemical analysis showed positive epithelial cell adhesion molecule (Ep-CAM) expression, the target molecule of Wnt/beta-catenin signalling, only in non-responders. In vitro studies showed that activation of Wnt/beta-catenin signalling by glycogen synthesis kinase-3 inhibitor (6-bromoindirubin-3'-oxime (BIO)) induced chemoresistance to IFN-alpha/5-FU. BrdU-based cell proliferation ELISA and cell cycle analysis showed that concurrent addition of BIO and IFN-alpha/5-FU significantly to hepatoma cell cultures reduced the inhibitory effects of the latter two on DNA synthesis and accumulation of cells in the S-phase. The results indicate that activation of Wnt/beta-catenin signalling pathway induces chemoresistance to IFN-alpha/5-FU therapy and suggest that Ep-CAM is a potentially useful marker for resistance to such therapy, especially in IFNAR2-positive cases. British Journal of Cancer (2009) 100, 1647-1658. doi: 10.1038/sj.bjc.6605064 www.bjcancer.com Published online 28 April 2009 (C) 2009 Cancer Research UK
引用
收藏
页码:1647 / 1658
页数:12
相关论文
共 50 条
  • [21] Combined Intraarterial 5-fluorouracil and subcutaneous interferon-α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches
    Sakon, M
    Nagano, H
    Dono, K
    Nakamori, S
    Umeshita, K
    Yamada, A
    Kawata, S
    Imai, Y
    Iijima, S
    Monden, M
    CANCER, 2002, 94 (02) : 435 - 442
  • [22] Tyrosine Kinase Inhibitor PTK/ZK Enhances the Antitumor Effects of Interferon-α/5-Fluorouracil Therapy for Hepatocellular Carcinoma Cells
    Murakami, Masahiro
    Kobayashi, Shogo
    Marubashi, Shigeru
    Tomimaru, Yoshito
    Noda, Takehiro
    Wada, Hiroshi
    Eguchi, Hidetoshi
    Takeda, Yutaka
    Tanemura, Masahiro
    Umeshita, Koji
    Doki, Yuichiro
    Mori, Masaki
    Nagano, Hiroaki
    ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (02) : 589 - 596
  • [23] Tyrosine Kinase Inhibitor PTK/ZK Enhances the Antitumor Effects of Interferon-α/5-Fluorouracil Therapy for Hepatocellular Carcinoma Cells
    Masahiro Murakami
    Shogo Kobayashi
    Shigeru Marubashi
    Yoshito Tomimaru
    Takehiro Noda
    Hiroshi Wada
    Hidetoshi Eguchi
    Yutaka Takeda
    Masahiro Tanemura
    Koji Umeshita
    Yuichiro Doki
    Masaki Mori
    Hiroaki Nagano
    Annals of Surgical Oncology, 2011, 18 : 589 - 596
  • [24] A pilot study of interferon alpha and 5-fluorouracil in hepatocellular carcinoma
    Mughal, TI
    Koriech, OM
    ACTA ONCOLOGICA, 1996, 35 (02) : 248 - 248
  • [26] Anti-angiogenic effects of combination therapy of interferon-alpha and 5-fluorouracil in the treatment for advanced hepatocellular carcinoma
    Wada, Hiroshi
    Nagano, Hiroaki
    Yamamoto, Hirofumi
    Ota, Hideo
    Nakamura, Masato
    Damdinsuren, Bazarragchaa
    Noda, Takehiro
    Marubashi, Shigeru
    Miyamoto, Atsushi
    Takeda, Yutaka
    Umeshita, Koji
    Dono, Keizo
    Monden, Morito
    HEPATOLOGY, 2006, 44 (04) : 623A - 623A
  • [27] Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion
    Obi, S
    Yoshida, H
    Toune, R
    Unuma, T
    Kanda, M
    Sato, S
    Tateishi, R
    Teratani, T
    Shiina, S
    Omata, M
    CANCER, 2006, 106 (09) : 1990 - 1997
  • [28] COMBINATION OF 5-FLUOROURACIL, INTERFERON, AND NIVOLUMAB IN THE TREATMENT OF FIBROLAMELLAR CARCINOMA
    Gottlieb, Sara
    Gliksberg, Ariel
    Kent, Paul
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S71 - S71
  • [29] Combined intraarterial 5-fluorouracil and intramuscular interferon-alpha therapy for advanced hepatocellular carcinoma
    Ohmoto, K
    Iguchi, Y
    Mimura, N
    Tsuduki, M
    Shimabara, M
    Kuboki, M
    Yamamoto, S
    HEPATO-GASTROENTEROLOGY, 2003, 50 (54) : 1780 - 1782
  • [30] Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma
    Uchino, Koji
    Obi, Shuntaro
    Tateishi, Ryosuke
    Sato, Shinpei
    Kanda, Miho
    Sato, Takahisa
    Arano, Toru
    Enooku, Kenichiro
    Goto, Eriko
    Masuzaki, Ryota
    Nakagawa, Hayato
    Asaoka, Yoshinari
    Kondo, Yuji
    Yamashiki, Noriyo
    Goto, Tadashi
    Shiina, Shuichiro
    Omata, Masao
    Yoshida, Haruhiko
    Koike, Kazuhiko
    JOURNAL OF GASTROENTEROLOGY, 2012, 47 (10) : 1152 - 1159